| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| laropiprant | hmg-coa reductase | NA | Successful target | TTD , DGIDB | Coronary Arteriosclerosis[MeSHID:D003324] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronary heart disease[MeSHID:D003327] Arteriosclerosis[MeSHID:D001161] |
0.45 | phase 4 | unknown |
| laropiprant | prostaglandin d2 receptor | NA | Clinical trial target | TTD , DGIDB | Coronary Arteriosclerosis[MeSHID:D003324] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronary heart disease[MeSHID:D003327] Arteriosclerosis[MeSHID:D001161] |
3.5 | phase 4 | unknown |
| laropiprant | prostaglandin d2 receptor | NA | Clinical trial target | TTD , DGIDB | Coronary Arteriosclerosis[MeSHID:D003324] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronary heart disease[MeSHID:D003327] Arteriosclerosis[MeSHID:D001161] |
3.5 | phase 4 | antagonist |
| laropiprant | prostaglandin d2 receptor 2 | NA | Clinical trial target | TTD , DGIDB | Coronary Arteriosclerosis[MeSHID:D003324] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronary heart disease[MeSHID:D003327] Arteriosclerosis[MeSHID:D001161] |
0.51 | phase 4 | unknown |
| laropiprant | prostaglandin e2 receptor ep2 | NA | Successful target | TTD , DGIDB | Coronary Arteriosclerosis[MeSHID:D003324] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronary heart disease[MeSHID:D003327] Arteriosclerosis[MeSHID:D001161] |
0.65 | phase 4 | unknown |
| laropiprant | prostaglandin f2-alpha receptor | NA | Successful target | TTD , DGIDB | Coronary Arteriosclerosis[MeSHID:D003324] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronary heart disease[MeSHID:D003327] Arteriosclerosis[MeSHID:D001161] |
0.53 | phase 4 | unknown |
| laropiprant | prostacyclin receptor | NA | Successful target | TTD , DGIDB | Coronary Arteriosclerosis[MeSHID:D003324] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronary heart disease[MeSHID:D003327] Arteriosclerosis[MeSHID:D001161] |
0.53 | phase 4 | unknown |
| laropiprant | thromboxane a2 receptor | NA | Successful target | TTD , DGIDB | Coronary Arteriosclerosis[MeSHID:D003324] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronary heart disease[MeSHID:D003327] Arteriosclerosis[MeSHID:D001161] |
0.43 | phase 4 | unknown |
| click here to return to the previous page | ||||||||